Cancer Biopsies Market is segmented By Product (Kits and Consumables, Instruments), By Type (Liquid Biopsies, Tissue Biopsies, Others), By Application (Breast Cancer, Cervical Cancers, Lung Cancers, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
Cancer Biopsies Market Overview
Cancer Biopsies Market is expected to reach a CAGR of 13.8% during the forecast period (2023-2030).
The main way to diagnose most types of cancer is by biopsy. Only a biopsy can make a diagnosis while other tests can suggest that cancer is present. During biopsy, a small amount of tissue is removed to examine under a microscope.
Cancer Biopsies Market Scope
|
Metrics |
Details |
|
Market CAGR |
13.8% |
|
Segments Covered |
By Product, By Type, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Know More Insights - Download Sample
Cancer Biopsies Market Dynamics
The growing prevalence of oncology indications and development in biopsy techniques will drive the market growth.
The growing prevalence of oncology will drive the cancer biopsies market
Worldwide, the International Agency for Research on Cancer (IARC) estimates that 1 in 5 people during their lifetime develop cancer, and 1 in 11 women die from it. These new estimates suggest that more than 50 million people are living within five years of a past cancer diagnosis. Globally, breast cancer represents 1 in 4 cancers diagnosed among women. Colorectal, lung, cervical, and thyroid cancers are also common among women.
The regulatory route leading to the therapeutic indications of new compounds and extensions of indications of already approved ones is a challenging process. If new anticancer drugs reach the market with a lack of complete evidence, this usually leads regulators to request additional data, post-approval commitments, or restrictions in therapeutic indications. In recent years, a record number of new oncology drugs have been approved, with new treatment options for patients. Despite various levels of pipeline activity, oncology remains a challenging area for research and development. 15 new oncology therapeutic drugs were launched in 2019 for 17 indications. Over half of the new therapies are an oral formulation, have an orphan indication, or include a predictive biomarker on their label.
The development in biopsy techniques will drive the market growth
A procedure in which a sample of cells or a piece of tissue is removed from the body and analyzed in a laboratory is known as a biopsy. If a patient experiences certain signs and symptoms or if the doctor has identified an area of concern, then the patient may undergo a biopsy to determine whether they have cancer or some other condition. While imaging tests, such as X-rays, help detect masses or areas of abnormality, they alone can't differentiate cancerous cells from noncancerous cells. For most cancers, the only diagnosis is to perform a biopsy to collect cells for closer examination.
Liquid biopsy is a minimally invasive test for cancer genetic status based on circulating tumor cells, circulating tumor DNA (ctDNA), and other tumor-derived materials in blood plasma. Although the time resolution and minimal invasiveness are attractive features of liquid biopsy, the limited amount of ctDNA in plasma poses a problem. Recent developments in next-generation sequencing (NGS)-based technology and digital PCR have improved the accuracy of liquid biopsy. Molecular barcoding technology, in particular in NGS-based methods, i.e., before amplification tagging molecular barcodes to cell-free DNA, reduces technical errors by validating the consensus of sequences, leading to marked improvement of the detection limit and accuracy. However, substitutions caused by somatic mutations and DNA damage originating from normal cells are obstacles to the sensitive detection of mutations on ctDNA. Since there are only a few clinical applications, a deeper understanding of ctDNA biology and more advanced analytical technology is needed for the practical application of liquid biopsy.
Lack of awareness and disadvantages related to biopsy procedures will hamper the cancer biopsies market
A biopsy is an important part of a cancer diagnosis. If the doctor finds cancer, the results of a biopsy can also help them tailor the right treatment plan for the patient and the specific type of cancer. But some people wonder if a biopsy could have other effects on their body, including whether it may lead to cancer spreading.
Every medical procedure has risks. Biopsies carry a small risk of infection and bleeding. In recent studies, scientists have worked to quantify the risks and benefits of biopsies to inform patients and fellow physicians better. Tumor seeding or needle seeding is rare when the needle inserted into a tumor during a biopsy dislodges and spreads cancer cells. It is sometimes called needle track or tract seeding because the cancer cells grow along the needle’s track. One of the major disadvantages of TRUS biopsy is that it has a false-negative rate of up to 30%. The main reason is that the samples are essentially taken blindly due to the unknown location of the tumor. However, the standard systematic biopsy, which takes 12 tissue cores from the prostate, picks up only about half of all tumor foci, with a sensitivity of only 53%. The false-negative rate and the dependence upon blind sampling mean that if the original symptoms persist or the PSA level remains high or rises, a repeat biopsy is required. Repeat biopsies are now often recommended to be performed under MRI guidance (using multiparametric MRI) alone or in combination with an ultrasound. The transperineal biopsy route is also shown to increase the accuracy of detection of prostate cancers, especially from the anterior and transitional zone.
COVID-19 Impact Analysis
During the COVID 19 pandemic medical practices have been affected due to several protocols. The biopsy procedures for the diagnosis of cancer involved in this pandemic have been affected. People are scared to undergo a diagnosis of cancer due to the risk of COVID-19, so there has been an impact on the cancer biopsies market.
Cancer Biopsies Market Segment Analysis
Kits and consumables segment will dominate the cancer biopsies market
Assembling all the products for a procedure can be time-consuming. Ready-made packs contain products you need, resulting in decreased time consumption. Merit Medical customizes procedural packs to specifications that meet the clinical requirements.
C Test Medical has introduced the swivel biopsy test for the early detection and prevention of oral cancer. The patented C Test comprises a simple, easy-to-use kit that can detect oral cancer 4 to 5 years in advance, which is even before malignancy strikes.
The other technical advantage is the high rate of accuracy owing to the dual test format of brush & swivel and the digitalized reporting. Sysmex Europe GmbH, together with Sysmex Inostics GmbH, has announced that they will launch the Plasma-SeqSensei™ liquid biopsy research use only (RUO) kits for colorectal cancer (CRC), non-small cell lung cancer (NSCLC), melanoma, and thyroid cancer.
Liquid biopsies type will dominate the market in the forecast period
The concept of precision medicine over the last decades has renewed dramatically the field of medical oncology. The introduction of patient-tailored therapies has improved significantly all measurable outcomes. A revolutionary technique Liquid biopsy is opening unexpected previous perspectives. It consists of the isolation and detection of exosomes, DNA circulating tumor cells, and circulating tumors, as a source of proteomic and genomic information in cancer patients.
Due to newly developed techniques and next-generation sequencing analyses, many technical hurdles have been resolved, in a wide range of settings allowing a broad application of liquid biopsy. Initially correlated to prognosis, liquid biopsy data are now being studied for cancer diagnosis, hopefully including screenings, and most importantly, for predicting response or resistance to given treatments. In particular, identifying specific mutations in target genes can aid in therapeutic decisions, both in the appropriateness of treatment and the advanced identification of secondary resistance, aiming to diagnose disease progression early. Still, the application is far from reality, but ongoing research leads the way to a new era in oncology. Liquid biopsy has the advantages of being non-invasive, rapid, precise, and especially real-time. It can also overcome the heterogeneity of tumors and may replace tissue biopsy in the future.
The breast cancer segment dominated the cancer biopsies market
Breast cancer arises in the (epithelium) lining cells of the ducts or lobules in the glandular breast tissue. The cancerous growth is confined initially, to the lobule or duct, where it generally causes no symptoms and has minimal potential for spread. Over time, these in situ cancers progress and invade the surrounding breast tissue then spread to the nearby lymph nodes or other organs in the body (distant metastasis). If a woman dies from breast cancer, it is because of widespread metastasis.
Breast cancer treatment can be effective highly, especially when the disease is identified early. Breast cancer treatment often consists of surgical removal, radiation therapy, and medication (hormonal therapy, chemotherapy, and targeted biological therapy) to treat microscopic cancer that has spread from the breast tumor through the blood. Treatments that can prevent cancer growth and spread thereby saving lives. Globally, in 2020 there were 2.3 million women diagnosed with breast cancer and 685 000 deaths. Making it the world’s most prevalent cancer at the end of 2020, there were 7.8 million women alive who were diagnosed with it in the past five years. Women have more lost disability-adjusted life years to breast cancer than any other cancer type. In every country of the world breast cancer occurs in women at any age after puberty but with increasing rates later in life.
Cancer Biopsies Market Geographical Share
North America region will dominate the cancer biopsies market
The increasing incidence rate of cancer and the presence of major key players will drive the market in this region
In the U.S. in 2021, an estimated 281,550 new cases of invasive breast cancer in women are expected to be diagnosed along with 49,290 new cases of non-invasive (in situ) breast cancer. The U.S. FDA announced that the agency would hold a public meeting of the Oncologic Drugs Advisory Committee to discuss six indications granted accelerated approval that has since reported results from a confirmatory trial that have not verified clinical benefit. These products are being used under approval accelerated to treat breast, urothelial, gastric, and hepatocellular cancers.
The U.S. FDA approved the first diagnostic liquid biopsy companion that uses next-generation sequencing technology to identify a deadly form of metastatic non-small cell lung cancer in specific types of mutations of the epidermal growth factor receptor gene in patients. This is the first approval with two technologies combined NGS and liquid biopsy in one diagnostic test to guide treatment decisions.
Cancer Biopsies Market Companies
Major key players in the cancer biopsies market are Qiagen N.V., Illumina, Inc., ANGLE Plc, BD (Becton, Dickinson, and Company), Myriad Genetics, Hologic, Inc., Biocept, Inc., Danaher, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health, Exact Sciences Corporation, Freenome Holdings, Inc., Biodesix (Integrated Diagnostics), Oncimmune, Epigenomics AG, HelioHealth (Laboratory for Advanced Medicine), Genesystems, Inc. (Genesys Biolabs), Chronix Biomedical, Inc., Personal Genome Diagnostics Inc.
Key Companies to Watch
Illumina, Inc.
Overview: At Illumina,the goal is to apply innovative technologies and revolutionary assays to analyze the function and genetic variation, making studies possible that were not imaginable just a few years ago. These will help make the realization of personalized medicine possible. With such rapid advancement in technology taking place, it is mission-critical to have innovative and flexible solutions, scalable, and complete with industry-leading support and service.
Product Portfolio: It is a global company that places high value on the rapid delivery of solutions, collaborative interactions, and prioritizing the needs of its customers. They strive for protein analysis to serve as tools for disease research, drug development, and molecular tests in the clinic.
Key Development: On April 22, 2021, Illumina, Inc. and Kartos Therapeutics, Inc. has announced a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s comprehensive genomic profiling assay, TruSight™ Oncology 500 (TSO 500). This companion diagnostic for multiple hematologic indications will first use TSO 500 with whole peripheral blood as a diagnostic sample type.
The cancer biopsies market report would provide access to an approx. 60 market data table, 52 figures, and 180 pages.
